Accessed on October 2, 2007.
(To view Web sites, please copy and paste the URL into your browser)
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.
Safe Harbor Statement*
This press release may contain statements which address such key issues
as growth strategy, future financial results, market positions, product
development, pharmaceutical products in the pipeline, and product approvals
of Organon. Such statements should be carefully considered, and it should
be understood that many factors could cause forecasted and actual results
to differ from these statements. These factors include, but are not limited
to, price fluctuations, currency fluctuations, progress of drug
development, clinical testing and regulatory approval, developments in raw
material and personnel costs, pensions, physical and environmental risks,
legal issues, and legislative, fiscal, and other regulatory measures.
Stated competitive positions are based on management estimates supported by
information provided by specialized external agencies. For a more
comprehensive discussion of the risk factors affecting our business please
see our Annual Report on Form 20-F filed with the United States Securities
and Exchange Commission
Copyright©2007 PR Newswire.
All rights reserved